On Wednesday, Trina Solar Limited (ADR) (NYSE:TSL)’s shares declined -4.07% to $9.44.
Trina Solar Limited (TSL) a global leader in photovoltaic (“PV”) modules, solutions, and services, declared that its TSM-PE05A and TS-PE14A polycrystalline modules (“the Modules”) have received UL1500V certification from Underwriters Laboratories (“UL”), a global independent safety science company.
The UL1500V award certifies that the Modules are allowed to be used in PV systems with a maximum system voltage of 1500V, significantly higher than the existing 1000V of most modules on the market. Furthermore, the 1500V certification demonstrates that the Modules produced by Trina Solar meet higher technical standards and quality requirements. The higher system voltage modules allow our customers to design their PV systems with longer string length. It significantly reduces the number of component in the balance of the system (BOS), and reduces the cost per unit of power (US$/W) of BOS. It also boosts the system performance by reducing the system loses.
Trina Solar Limited operates as an integrated solar-power products manufacturer and solar system developer in the People’s Republic of China, Europe, the United States, and other Asia Pacific regions. The company designs, develops, manufactures, and sells photovoltaic (PV) modules comprising monocrystalline and multicrystalline PV modules ranging in various power outputs for use in residential, commercial, industrial, and other solar power generation systems.
Lennar Corporation (NYSE:LEN)’s shares gained 2.31% to $53.19.
Lennar Corporation (LEN), one of the nation’s largest homebuilders, declared the formation of Lennar Multifamily Venture (“LMV” or the “Venture”), an equity fund between Lennar Multifamily Communities (“LMC”) and global sovereign and institutional investors targeting investments in class-A multifamily development assets in 25 top metropolitan markets in the United States.
The new Venture will aim to provide superior risk-adjusted returns through a “develop-to-core” strategy - developing multifamily communities and then holding those communities in a portfolio long term for cash flow. LMV will focus on the top growth and gateway markets in the United States, which are characterized by strong long-term demand fundamentals and constrained supply, and will capitalize on Lennar’s deep construction expertise to build multifamily communities at an attractive cost basis. The Venture is predictable to build a combination of garden, mid-rise and high-rise properties. The Venture will benefit from LMC’s fully integrated development administration, construction administration, property administration, and asset administration platforms.
Lennar Corporation, together with its auxiliaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Homebuilding Southeast Florida, Homebuilding Houston, Financial Services, Rialto, and Lennar Multifamily segments.
At the end of Wednesday’s trade, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)‘s shares surged 8.10% to $5.74.
Catalyst Pharmaceuticals, Inc. (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, declared the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for Firdapse® for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse® has received Breakthrough Therapy Designation from the FDA for the treatment of LEMS, in addition to orphan drug designations for LEMS and congenital myasthenic syndromes (CMS).
The Breakthrough Therapy Designation is designed to convey all of the fast track program features, in addition to more intensive FDA guidance on an efficient drug development program. The Fast Track Designation is designed to facilitate the development and expedite the review of drugs that treat serious, life-threatening conditions and that address unmet medical needs. The Fast Track process allows a company to submit individual modules of its NDA for review by the FDA as they are accomplished.
Catalyst Pharmaceuticals, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.
Enbridge Inc (USA) (NYSE:ENB), ended its Wednesday’s trading session with -3.93% loss, and closed at $42.77.
Enbridge Energy Partners, L.P. ( EEP) (will host a webcast conference call to talk about its 2015 second quarter financial results as follows:
Webcast Information
Event: Q2 2015 Enbridge Energy Partners L.P. Earnings Call
Date: Thursday, July 30, 2015
Time: 5:00 p.m. Eastern Time
Enbridge Inc. operates as an energy transportation and distribution company in the United States and Canada. Its Liquids Pipelines segment operates common carrier and contract crude oil, natural gas liquids (NGL), and refined products pipelines and terminals. The company’s Gas Distribution segment operates as a natural gas utility that serves residential, commercial, and industrial customers in Central and Eastern Ontario, and Northern New York State, in addition to in Quebec and New Brunswick. Its Gas Pipelines, Processing and Energy Services segment has interests in natural gas pipelines, counting the Vector Pipeline and transmission and gathering pipelines in the Gulf of Mexico, in addition to holds an interest in Aux Sable, a natural gas fractionation and extraction facility. This segment is also involved in the renewable energy projects, such as wind, solar, and geothermal projects with a generating capacity of about 2,200 MW.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.